Acute Renal Failure

Kidney Diseases

Chronic Kidney Disease

Coronary (Artery); Disease

Biomarker Effectiveness Analysis in Contrast Nephropathy (BEACON)

Biomarker Effectiveness Analysis in Contrast Nephropathy

Raghavan Murugan

M.D.

University of Pittsburgh

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

US Department of Veterans Affairs

Erythrocytosis

Mountain Sickness

N-acetylcysteine

Acetazolamide

1 (or 2 in the placebo group) empty gel capsules

Placebo pills

Chronic mountain sickness clinic

Study of Cobalt's Role in Excessive Erythrocytosis Among High Altitude Dwellers in Cerro de Pasco, Peru

Randomized Controlled Trial of N-acetylcysteine and Acetazolamide in Treatment of Chronic Mountain Sickness

Spun hematocrit measured on portable machine

Analyzed using portable machine. The values analyzed include serum pH, partial pressure of carbon dioxide, partial pressure of oxygen, and serum bicarbonate.

Serum hormone that stimulates red blood cell production

Ratio of urine total protein to urine creatinine

Chronic Mountain Sickness Score Absent Mild Moderate Severe Headache 0 +1 +2 +3 Dizziness 0 +1 +2 +3 Failing Memory 0 +1 +2 +3 Fatigue 0 +1 +2 +3 Breathlessness 0 +1 +2 +3 Sleep disturbances 0 +1 +2 +3 Tinnitus 0 +1 +2 +3 Anorexia 0 +1 +2 +3 Cyanosis of lips, face, or fingers 0 +1 +2 +3 Hyperemia or prominent capillaries conjunctivae or laryngopharynx 0 +1 +2 +3

Electrolytes, specifically monitoring serum potassium to treat serious hypokalemia (serum potassium < 3.0 meQ/L).

University of Colorado, Denver

Universidad Peruana Cayetano Heredia

Jackson, Brian, M.S.

Thomas H Maren Foundation

Placebos for acetaminophen and N-acetylcysteine

Acetaminophen 1 gm every 6 hours and N-acetylcysteine placebo

N-acetylcysteine IV infusion at 0.5 gm hourly and acetaminophen placebo

Acetaminophen 1 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly

Acetaminophen 1.5 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly

Aneurysmal Subarachnoid Hemorrhage

Cerebral Vasospasm

APAP 1 gm every 6 hours and N-acetylcysteine placebo

NAC IV infusion at 0.5 gm hourly and APAP placebo

APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly

APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly

Tristar Skyline Medical Center

Centennial Medical Center

St. Thomas Midtown Hospital

Vanderbilt University Medical Center

Acetaminophen in aSAH to Inhibit Lipid Peroxidation and Cerebral Vasospasm

Inhibition of Lipid Peroxidation and Cerebral Vasospasm by an Acetaminophen-Based Regimen in Patients With Aneurysmal Subarachnoid Hemorrhage

John Oates

Professor of Medicine

Vanderbilt University

National Institutes of Health (NIH)

National Institute of General Medical Sciences (NIGMS)

Cardiac Surgery and Cardiopulmonary Bypass

Placebo

Austin Hospital

High-Dose N-Acetylcysteine in Cardiac Surgery

High-Dose N-Acetylcysteine in Cardiac Surgery Patients at High-Risk of Postoperative Renal Dysfunction.

Austin Health

Heart Disease

Renal Insufficiency

Intravenous N-acetylcysteine

A Study of The Effectiveness of N-Acetylcysteine in Kidney Protection Following Cardiopulmonary Bypass

A Randomized Placebo Controlled Trial of Intravenous N-Acetylcysteine (NAC) As A Renal Protective Agent for Prevention of Renal Dysfunction Following Cardiopulmonary Bypass (CPB)

acetylcysteine/ictus

Biomarker Effectiveness Analysis in Contrast Nephropathy (BEACON)

Study of Cobalt's Role in Excessive Erythrocytosis Among High Altitude Dwellers in Cerro de Pasco, Peru

Acetaminophen in aSAH to Inhibit Lipid Peroxidation and Cerebral Vasospasm

High-Dose N-Acetylcysteine in Cardiac Surgery

A Study of The Effectiveness of N-Acetylcysteine in Kidney Protection Following Cardiopulmonary Bypass

Il database di erbe medicinali più completo supportato dalla scienza